Antibody-drug conjugates (ADCs) targeted therapy for advanced multiple myeloma or cervical cancer can cause significant off-target eye toxicity, with risks not widely known. Collaboration between oncologists and ophthalmologists is crucial, as recent studies have shown that some ADCs can lead to ocular toxicity. Ocular damage such as blurred vision, dry eyes, and light sensitivity have been reported in patients on these therapies, impacting their daily life. Preventive measures for ocular toxicity include the use of steroid eye drops or vasoconstrictor eye drops, with close monitoring by healthcare professionals. Collaboration between specialists is needed to manage these side effects effectively.
Source link
Eye Toxicities Are a Growing Concern With Certain ADCs
